IDH mutation is an early event in tumorigenesis and is seen uniformly distributed in all glioma cells making these mutations an ideal target for immunotherapy especially as a maintenance therapy for preventing recurrence of the tumors. Here, IDH2 is linked to central nervous system cancer.